Regencell Bioscience Holdings Limited (RGC)
RGC trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | RGC on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | Hong Kong |
| IPO year | 2021 |
| SEC CIK | 0001829667 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | Cayman Islands |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 20-F 2026-10-07 |
| Cash and burn | $14.2M cash; operating cash flow -$1.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 495,884,376 (2026-06-30); 494,488,908 a year earlier; 13,012,866 three years earlier. 3y figure adjusted for split (38-for-1 overall). | Cover page 2026-06-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-05-19 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | HTL International, LLC, Houston, Texas, United States | PCAOB Form AP 2026-10-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | Not filed | -$11.7M | -$7.7M | $14.2M | No debt tags | Needs four quarters | 20-F 2026-10-07 |
| FY 2025 2025-06-30 | Not filed | -$3.6M | -$3.1M | $2.4M | No debt tags | Needs four quarters | 20-F 2026-10-07 |
| FY 2024 2024-06-30 | Not filed | -$4.3M | -$4.0M | $3.0M | No debt tags | Needs four quarters | 20-F 2026-10-07 |
| FY 2023 2023-06-30 | Not filed | -$5.9M | -$5.0M | $1.6M | $11K | Needs four quarters | 20-F 2025-10-31 |
| FY 2022 2022-06-30 | Not filed | -$7.4M | -$5.3M | $6.4M | $16K | Needs four quarters | 20-F 2024-10-25 |
| FY 2021 2021-06-30 | Not filed | -$1.3M | -$767K | $59K | $3.7M | Needs four quarters | 20-F 2023-10-27 |
| FY 2020 2020-06-30 | Not filed | -$812K | -$727K | $387K | $3.1M | Needs four quarters | 20-F 2021-10-29 |
| FY 2019 2019-06-30 | Not filed | -$391K | -$391K | $243K | No debt tags | Needs four quarters | 20-F 2021-10-29 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-05-19 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-10-07 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-05-22 |
Source: SEC EDGAR submissions feed, 86 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.3% |
| 1 month | -39.7% |
| 3 months | -5.7% |
| Year to date | -76.5% |
| 1 year | -62.0% |
| From 52-week high | -90.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TRLV | Trulieve Cannabis Corp. Subordinate Voting Shares | $10.33 | -5.23% | $2.0B |
| RLX | RLX Technology Inc. | $1.53 | -1.92% | $1.9B |
| DFTX | Definium Therapeutics Inc. Common Shares | $30.16 | -5.99% | $4.1B |
| CRON | Cronos Group Inc. Common Share | $3.27 | -3.25% | $1.2B |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier